The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss

Genes and Development

Volumn 22, Issue 10, 2008, Pages 1337-1344

  Terzian, Tamara ^a   Suh, Young Ah ^a   Iwakuma, Tomoo ^b   Post, Sean M ^a   Neumann, Manja ^a   Lang, Gene A ^a   Van Pelt, Carolyn S ^a   Lozano, Guillermina ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gain of function; Metastasis; Mouse models; p53 stability

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE INHIBITOR 2A GENE; GENE LOSS; GENE MUTATION; GENETIC ANALYSIS; GENETIC STABILITY; IONIZING RADIATION; MDM2 GENE; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR SUPPRESSOR GENE;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTANT PROTEINS; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 44149121239     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1662908     Document Type: Article

References (57)

1. Appella, E. and Anderson, C.W. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268: 2764-2772.
2. Brooks, C.L. and Gu, W. 2003. Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15: 164-171.
3. Burns, T.F., Bernhard, E.J., and El-Deiry, W.S. 2001. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 20: 4601-4612.
4. Canman, C.E., Lim, D.S., Cimprich, K.A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M.B., and Siliciano, J.D. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679.
5. Chavez-Reyes, A., Parant, J.M., Amelse, L.L., de Oca Luna, R.M., Korsmeyer, S.J., and Lozano, G. 2003. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res. 63: 8664-8669.
6. Chuikov, S., Kurash, J.K., Wilson, J.R., Xiao, B., Justin, N., Ivanov, G.S., McKinney, K., Tempst, P., Prives, C., Gamblin, S.J., et al. 2004. Regulation of p53 activity through lysine methylation. Nature 432: 353-360.
7. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A.K., Moore, M., Finlay, C., and Levine, A.J. 1993. Gain of function mutations in p53. Nat. Genet. 4: 42-46.
8. Eischen, C.M., Weber, J.D., Roussel, M.F., Sherr, C.J., and Cleveland, J.L. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes & Dev. 13: 2658-2669.
9. Evans, S.C., Viswanathan, M., Grier, J.D., Narayana, M., El-Naggar, A.K., and Lozano, G. 2001. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20: 4041-4049.
10. Ferbeyre, G., de Stanchina, E., Lin, A.W., Querido, E., McCurrach, M.E., Hannon, G.J., and Lowe, S.W. 2002. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol. 22: 3497-3508.
11. Flores, E.R., Sengupta, S., Miller, J.B., Newman, J.J., Bronson, R., Crowley, D., Yang, A., McKeon, F., and Jacks, T. 2005. Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363-373.
12. Gannon, G., Mandriota, S.J., Cui, L., Baetens, D., Pepper, M.S., and Christofori, G. 2002. Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during β-cell carcinogenesis. Cancer Res. 62: 603-608.
13. Giaccia, A.J. and Kastan, M.B. 1998. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes & Dev. 12: 2973-2983.
14. Gu, W. and Roeder, R.G. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
15. Hall, P.A. and Lane, D.P. 1994. p53 in tumour pathology: Can we trust immunohistochemistry? - Revisited! J. Pathol. 172: 1-4.
16. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
17. Helton, E.S. and Chen, X. 2007. p53 modulation of the DNA damage response. J. Cell. Biochem. 100: 883-896.
18. Hermeking, H. and Eick, D. 1994. Mediation of c-Myc-induced apoptosis by p53. Science 265: 2091-2093.
19. Honda, R., Tanaka, H., and Yasuda, H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25-27.
20. Horn, H.F. and Vousden, K.H. 2007. Coping with stress: Multiple ways to activate p53. Oncogene 26: 1306-1316.
21. Iwakuma, T., Parant, J.M., Fasulo, M., Zwart, E., Jacks, T., de Vries, A., and Lozano, G. 2004. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene 23: 7644-7650.
22. Jacks, T., Remington, L., Williams, B.O., Schmitt, E.M., Halachmi, S., Bronson, R.T., and Weinberg, R.A. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1-7.
23. Jones, S.N., Roe, A.E., Donehower, L.A., and Bradley, A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
24. Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day III, R.S., Johnson, B.E., and Skolnick, M.H. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
25. Kamijo, T., Weber, J.D., Zambetti, G., Zindy, F., Roussel, M.F., and Sherr, C.J. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. 95: 8292-8297.
26. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R.W. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
27. Kubbutat, M.H., Jones, S.N., and Vousden, K.H. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299-303.
28. Lang, G.A., Iwakuma, T., Suh, Y.A., Liu, G., Rao, V.A., Parant, J.M., Valentin-Vega, Y.A., Terzian, T., Caldwell, L.C., Strong, L.C., et al. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
29. Lavin, M.F. and Gueven, N. 2006. The complexity of p53 stabilization and activation. Cell Death Differ. 13: 941-950.
30. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
31. Lozano, G. 2007. The oncogenic roles of p53 mutants in mouse models. Curr. Opin. Genet. Dev. 17: 66-70.
32. McDonnell, T.J., Montes de Oca Luna, R., Cho, S., Amelse, L.L., Chavez-Reyes, A., and Lozano, G. 1999. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J. Pathol. 188: 322-328.
33. Medema, R.H., Herrera, R.E., Lam, F., and Weinberg, R.A. 1995. Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. 92: 6289-6293.
34. Meek, D.W. 1994. Post-translational modification of p53. Semin. Cancer Biol. 5: 203-210.
35. Montes de Oca Luna, R., Wagner, D.S., and Lozano, G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
36. Nobori, T., Miura, K., Wu, D.J., Lois, A., Takabayashi, K., and Carson, D.A. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756.
37. Olive, K.P., Tuveson, D.A., Ruhe, Z.C., Yin, B., Willis, N.A., Bronson, R.T., Crowley, D., and Jacks, T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
38. ARF links the tumour suppressor p53 to Ras. Nature 395: 125-126.
39. Pomerantz, J., Schreiber-Agus, N., Liegeois, N.J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.W., et al. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
40. Prives, C. and Hall, P.A. 1999. The p53 pathway. J. Pathol. 187: 112-126.
41. Quelle, D.E., Zindy, F., Ashmun, R.A., and Sherr, C.J. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
42. Rocco, J.W. and Sidransky, D. 2001. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp. Cell Res. 264: 42-55.
43. Sakaguchi, K., Herrera, J.E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C.W., and Appella, E. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes & Dev. 12: 2831-2841.
44. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
45. Arf predisposes mice to tumorigenesis. Nature 413: 86-91.
46. Sherr, C.J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes & Dev. 12: 2984-2991.
47. Sherr, C.J. and McCormick, F. 2002. The RB and p53 pathways in cancer. Cancer Cell 2: 103-112.
48. Shieh, S.Y., Ikeda, M., Taya, Y., and Prives, C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
49. Sigal, A. and Rotter, V. 2000. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res. 60: 6788-6793.
50. Sjogren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. 1996. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. 88: 173-182.
51. Song, H., Hollstein, M., and Xu, Y. 2007. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat. Cell Biol. 9: 573-580.
52. Takagi, M., Absalon, M.J., McLure, K.G., and Kastan, M.B. 2005. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123: 49-63.
53. Vousden, K.H. 2006. Outcomes of p53 activation - Spoilt for choice. J. Cell Sci. 119: 5015-5020.
54. waf1/cip1. Genes & Dev. 8: 2817-2830.
55. Weisz, L., Oren, M., and Rotter, V. 2007. Transcription regulation by mutant p53. Oncogene 26: 2202-2211.
56. Zhang, Y., Xiong, Y., and Yarbrough, W.G. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.
57. INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res. 66: 10325-10331.